nContact Surgical is a medical device company that develops devices supporting endoscopic treatments for heart rhythm disorders.
nContact is a medical device company founded in 2005 with a mission to develop devices for the endoscopic treatment of arrhythmias, including atrial fibrillation (AF). The Numeris® Coagulation System with VisiTrax® is based on the unique integration of suction, perfusion, and RF energy to ensure the creation of visible, nonconductive, continuous, bi-atrial lesions on the epicardium of a beating heart.To date, the Numeris® Coagulation System with VisiTrax® is indicated for endoscopic coagulation of cardiac tissue in the United States. nContact has initiated IDE clinical studies for the treatment of AF in both open and closed chest procedures. The Numeris Coagulation System with VisiTrax has CE Mark approval inEurope for the coagulation of cardiac tissue for the treatment of AF and atrial flutter.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Nov 13, 2014 | Debt Financing | $20M | 1 | — | — | Detail |
Nov 10, 2010 | Series D | $16M | 1 | — | — | Detail |
Nov 30, 2007 | Series C | $8.49M | 1 | — | — | Detail |
Sep 27, 2006 | Series B | $7.49M | 1 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Hercules Capital | — | Debt Financing |
ZMV Associates | — | Series D |
Massey Burch Capital Corporation | — | Series C |